Epidemiology of activated protein C resistance and Factor V Leiden mutation in the Mediterranean region

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 3, Issue 1, 2011, Pages 1-11

  Jadaon, Mehrez M ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84928983946     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2011.037     Document Type: Review

References (140)

1. Dahlbäck B. Resistance to activated protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays. Pros and Cons. Thromb Haemost 73(5): 739-742, 1995. PMid:7482395
2. Rees DC, Cox M and Clegg JB. World distribution of factor V Leiden. Lancet 346(8983): 1133-1134, 1995. http://dx.doi.org/10.1016/S0140-6736(95)91803-5
3. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of Factor V Leiden in 4047 men and women. Implications for venous thrmoboembolism screening. JAMA. 1997;277:1305-1307 http://dx.doi.org/10.1001/jama.277.16.1305
4. Zivelin A, Griffin JH, Xu X, Pabinger I, Samama M, Conard J, Brenner B, Eldor A and Seligsohn U. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 89(2): 397-402, 1997. PMid:9002940
5. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited thrombophilia: Part 1. Thromb Haemost. 76(5):651-662, 1996. PMid:8950768
6. Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 74(4): 1-6, 1995. PMid:8578439
7. Kane WH and Davie EW. Blood coagulation factor V and VIII: structural and functional similarities and their relationship to haemorrhegic and thrombotic disorders. Blood 71(3): 539-555, PMid:3125864
8. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994;269:31869-31880. PMid:7989361
9. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to ctivated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993;90:1004-1008. http://dx.doi.org/10.1073/pnas.90.3.1004
10. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde HD, van der Velden PA and Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369(6475): 64-67, 1994. http://dx.doi.org/10.1038/369064a0 PMid:8164741
11. Dahlbäck B. Resistance to activated protein C caused by the factor V R506Q mutation is a common risk factor for venous thrombosis. Thromb Haemost. 1997;78:483-488. PMid:9198201
12. Faioni EM, Razzari C, Martinelli I, Panzeri D, Franchi F, Mannucci PM. Resistance to activated protein C in unselected patients with arterial and venous thrombosis. Am J Hematol. 1997;55:59-64 http://dx.doi.org/10.1002/(SICI)1096-8652(199706)55:2<59::AID-AJH2>3.0.CO;2-1
13. Hoagland LE, Triplett DA, Peng F, et al. APC-resistnace as measured by a Textarin time assay: comparison to the APTTbased method. Thromb Res. 1996;83:363-373. http://dx.doi.org/10.1016/0049-3848(96)00146-6
14. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994;94:2521-2524. http://dx.doi.org/10.1172/JCI117623 PMid:7989612 PMCid:330087
15. Alderborn A, Siegbahn A, Wadelius C. Venous thrombosis: factor V G1691A genetypeing related to APC resistance measured by 2 methods. Eur J Haematol. 1997;58:229-232. http://dx.doi.org/10.1111/j.1600-0609.1997.tb01659.x
16. Bontempo FA, Hassett AC, Faruki H, et al. The factor V Leiden mutation: spectrum of thrombotic events and laboratory evaluation. J Vasc Surg. 1997;25(2):271-275. http://dx.doi.org/10.1016/S0741-5214(97)70348-3
17. Florell SR, Rodgers GM. Inherited thrombotic disorders: An update. Am J Hematol. 1997;54:53-60. http://dx.doi.org/10.1002/(SICI)1096-8652(199701)54:1<53::AID-AJH8>3.0.CO;2-3
18. Samama MM, Simon D, Horellou MH, et al. Diagnosis and clinical characteristics of inherited activated protein C resistance. Haemostasis. 1996;26:315-330. PMid:8979137
19. Bengtsson A, Zöller B, de Frutos PG, Dahlbäck B and Sturfelt G. Factor V:Q506 mutation and anticardiolipin antibodies in systemic lupus erythematosus. Lupus 5(6): 598-601, 1996. http://dx.doi.org/10.1177/096120339600500607 PMid:9116703
20. Beauchamp NJ, Daly ME, Hampton KK, Cooper PC, Preston FE and Peake IR. High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis. Br J Haematol 88(1): 219-222, 1994. http://dx.doi.org/10.1111/j.1365-2141.1994.tb05005.x PMid:7803250
21. Herrmann FH, Koesling M, Schroder W, Altman R, Jimenez Bonilla R, Lopaciuk S, Perez-Requejo JL and Singh JR. Prevalence of factor V Leiden mutation in various populations. Genet Epidemiol 14(4):403-11, 1997. http://dx.doi.org/10.1002/(SICI)1098-2272(1997)14:4<403::AID-GEPI5>3.0.CO;2-3
22. Aschka I, Aumann V, Bergmann F, Budde U, Ebert W, Eckhof-Donovan S, Krey S, Nowak-Gottl U, Schobess R, Sutor AH, Wendisch J and Schneppenheim R. Prevalence of factor V Leiden in children with thrombo-embolism. Eur J Pediatr 155(12): 1009-1014, 1996. http://dx.doi.org/10.1007/BF02532520 PMid:8956934
23. Schröder W, Koesling M, Wulff K, Wehnert M, Herrmann FH. Large-scale screening for factor V Leiden mutation in a northeastern German population. Haemostasis. 1996;26:233-6.
24. Hainaut P, Azerad MA, Lehmann E, Schlit AF, Zech F, Heusterspreute M, Philippe M, Col C, Lavenne E and Mariau M. Prevalence of activated protein C resistance and analysis of clinical profile in thromboembolic patients. A Belgian prospective study. J intern Med 241(5): 427-433, 1997. http://dx.doi.org/10.1046/j.1365-2796.1997.139145000.x PMid:9183312
25. Simkova M, Batorova A, Dostalova K, Pozgayova S, Simko F, Kovacs L. Factor V Leiden in patients with venous thrombosis in Slovak population. Gen Physiol Biophys. 2004;23:435-442 PMid:15815078
26. Hudecek J, Dobrotová M, Hybenová J, Ivanková J, Melus V, Pullmann R, Kubisz P. Factor V Leiden and the Slovak population. Vnitr Lek. 2003;49:845-850 PMid:14689680
27. Melichart M, Kyrle PA, Eichnger S, Rintelen C, Mannhalter C, Pabinger I. Thrombotic tendency in 75 symptomatic, unrelated patients with APC resistance. Wien Klin Wochenschr. 1996;108:607-610 PMid:8921576
28. Nagy A, Melegh B, Losonczy H. Study of the Leiden mutation (factor VQ506), the most frequent cause of thrombophilia, in 116 thrombosis patients. Orv Hetil. 1997;138:2797-2800 PMid:9411348
29. Stankovics J, Melegh B, Nagy A, Kis A, Molnar J, Losonczy H, Schuler A, Kosztolanyi G. Incidence of factor V G1681A (Leiden) mutation in samplings from the Hungarian population. Orv Hetil. 1998;139:1161-1163 PMid:9613165
30. Djordjevic V, Rakicevic LJ, Mikovic D, Kovac M, Miljic P, Radojkovic D, Savic A. Prevalence of factor V leiden, factor V cambridge, factor II G20210A and methylenetetrahydrofolate reductase C677T mutations in healthy and thrombophilic Serbian populations. Acta Haematol. 2004;112:227-229. http://dx.doi.org/10.1159/000081280 PMid:15564739
31. Gurgey A, Mesci L. The prevalence of factor V Leiden (1691G A) mutation in Turkey. Turk J Pediatr. 1997;39:313-315 PMid:9339109
32. Olave T, Cornudella R, Homs C, Azaceta G, Tirado I, Gutierrez M. Incidence and clinical manifestations of activated protein C resistance and factor V Leiden in young patients with venous thromboembolic disease in Spain. Haematologica. 1998;83:378-80 PMid:9592991
33. García-Hernández MC, Romero Casanova A, Marco Vera P. Clinical comments on genetic marker prevalence (factor V Leiden, prothrombin 20210A and homozygous methylenetetrahydrofolate reductase form [Ho-MTHFR]): based on a study conducted in Health Department No. 19 of the Valencian Community. Rev Clin Esp. 2007;207:26-28. PMid:17306151
34. Aznar J, Vayá A, Estellés A, Mira Y, Seguí R, Villa P, Ferrando F, Falcó C, Corella D, España F. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives. Haematologica. 2000;85:1271-1276 PMid:11114134
35. González Ordóñez AJ, Medina Rodriguez JM, Martín L, Alvarez V, Coto E. The O blood group protects against venous thromboembolism in individuals with the factor V Leiden but not the prothrombin (factor II G20210A) mutation. Blood Coagul Fibrinolysis. 1999; 10: 303-307 http://dx.doi.org/10.1097/00001721-199907000-00013
36. Vargas M, Soto I, Pinto CR, Urgelles MF, Batalla A, Rodriguez-Reguero J, Cortina A, Alvarez V, Coto E. The prothrombin 20210A allele and the factor V Leiden are associated with venous thrombosis but not with early coronary artery disease. Blood Coagul Fibrinolysis. 1999;10:39-41 http://dx.doi.org/10.1097/00001721-199901000-00006
37. Ricart JM, Vayá A, Todolí J, Calvo J, Villa P, Estellés A, España F, Santaolaria M, Corella D, Aznar J. Thrombophilic risk factors and homocysteine levels in Behçet's disease in eastern Spain and their association with thrombotic events. Thromb Haemost. 2006;95(4):618-624 PMid:16601831
38. Leroyer C, Mercier B, Escoffre M, Ferec C, Mottier D. Factor V Leiden prevalence in venous thromboembolism patients. Chest 1997;111: 1603-1606 http://dx.doi.org/10.1378/chest.111.6.1603 PMid:9187182
39. Mansourati J, Da Costa A, Munier S, Mercier B, Tardy B, Ferec C, Isaaz K, Blanc JJ. Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb Haemost. 2000;83:822-825 PMid:10896232
40. Meyer G, Emmerich J, Helley D, Arnaud E, Nicaud V, Alhenc-Gelas M, Aiach M, Fischer A, Sors H, Fiessinger JN. Factors V leiden and II 20210A in patients with symptomatic pulmonary embolism and deep vein thrombosis. Am J Med. 2001;110:12-15 http://dx.doi.org/10.1016/S0002-9343(00)00653-7
41. Mazoyer E, Ripoll L, Gueguen R, Tiret L, Collet JP, dit Sollier CB, Roussi J, Drouet L; FITENAT Study Group. Prevalence of factor V Leiden and prothrombin G20210A mutation in a large French population selected for nonthrombotic history: geographical and age distribution. Blood Coagul Fibrinolysis. 2009;20(7):503-510 http://dx.doi.org/10.1097/MBC.0b013e32832f5d7a
42. Bauder F, Ducout L, Guerre C, Freyburger G. Activated protein C (APC) resistance: does it exist in Basques? Br J Haematol. 1997;99(3):712-713 PMid:9401095
43. Zabalegui N, Montes R, Orbe J, Ayape ML, Medarde A, Páramo JA, Rocha E. Prevalence of FVR506Q and prothrombin 20210A mutations in the Navarrese population. Thromb Haemost. 1998;80:522-523 PMid:9759640
44. Simioni P, Prandoni P, Lensing AW, Scudeller A, Sardella C, Prims MH, Villatta S, Dazzi F, Girolami A. The risk of recurrent venous thromboembolism in patients with an Arg506 G mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997; 336:399-403 http://dx.doi.org/10.1056/NEJM199702063360602 PMid:9010145
45. Sottilotta G, Mammì C, Furlò G, Oriana V, Latella C, Trapani Lombardo V. High incidence of factor V Leiden and prothrombin G20210A in healthy southern Italians. Clin Appl Thromb Hemost. 2009;15:356-359
46. Gessoni G, Valverde S, Canistro R, Manoni F. Factor V Leiden in Chioggia: a prevalence study in patients with venous thrombosis, their blood relatives and the general population. Blood Transfus. 2010;8:193-195 PMid:20671880 PMCid:2906187
47. Martinelli I, Battaglioli T, Bucciarelli P, Passamonti SM, Mannucci PM. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. Circulation. 2004;110:566-570 http://dx.doi.org/10.1161/01.CIR.0000137123.55051.9B PMid:15262837
48. Mikovic D, Rakicevic L, Kovac M, Radojkovic D. Prevalence of factor V Leiden mutation in Yugoslav thrombophilic patients and its relationship to the laboratory diagnosis of APC resistance. Thromb Haemost. 2000;84:723-724 PMid:11057877
49. Bedencic M, Bozic M, Peternel P, Stegnar M. Major and potential prothrombotic genotypes in patients with venous thrombosis and in healthy subjects from Slovenia. Pathophysiol Haemost Thromb. 2008;36:58-63 PMid:19127083
50. Cikes V, Abaza I, Krzelj V, Terzic IM, Tafra R, Trlaja A, Marusic E, Terzic J. Prevalence of factor V Leiden and G6PD 1311 silent mutations in Dalmatian population. Arch Med Res. 2004;35:546-548 http://dx.doi.org/10.1016/j.arcmed.2004.07.005 PMid:15631882
51. Coen D, Zadro R, Honovic L, Banfic L, Stavljenic Rukavina A. Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism. Croat Med J. 2001;42:488-492 PMid:11471205
52. Jukic I, Bingulac-Popovic J, Dogic V, Babic I, Culej J, Tomicic M, Vuk T, Sarlija D, Balija M. ABO blood groups and genetic risk factors for thrombosis in Croatian population. Croat Med J. 2009;50:550-558 http://dx.doi.org/10.3325/cmj.2009.50.550 PMCid:2802088
53. Mekaj Y, Zhubi B, Hoxha H, Belegu R, Mekaj A, Miftari E, Belegu M. Prevalence of resistence to activated protein C (APCresistance) in blood donors in Kosovo. Bosn J Basic Med Sci. 2009;9:329-334 PMid:20002000
54. Hatzaki A, Anagnostopoulou E, Metaxa-Mariatou V, Melissinos C, Philalithis P, Iliadis K, Kontaxis A, Liberatos K, Pangratis N, Nasioulas G. The impact of heterozygosity for the factor V Leiden and factor II G20210A mutations on the risk of thrombosis in Greek patients. Int Angiol. 2003;22:79-82 PMid:12771861
55. Ioannou HV, Mitsis M, Eleftheriou A, Matsagas M, Nousias V, Rigopoulos C, Vartholomatos G, Kappas AM. The prevalence of factor V Leiden as a risk factor for venous thromboembolism in the population of North-Western Greece. Int Angiol. 2000;19:314-318 PMid:11305729
56. Antoniadi T, Hatzis T, Kroupis C, Economou-Petersen E, Petersen MB. Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in a Greek population of blood donors. Am J Hematol. 1999;61:265-267 http://dx.doi.org/10.1002/(SICI)1096-8652(199908)61:4<265::AID-AJH8>3.0.CO;2-#
57. Lambropoulos AF, Foka Z, Makris M, Daly M, Kotsis A, Makris PE. Factor V Leiden in Greek thrombophilic patients: relationship with activated protein C resistance test and levels of thrombin-antithrombin complex and prothrombin fragment 1 + 2. Blood Coagul Fibrinolysis. 1997;8:485-489 http://dx.doi.org/10.1097/00001721-199711000-00001
58. Limdi NA, Beasley TM, Allison DB, Rivers CA, Acton RT. Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy. Blood Cells Mol Dis. 2006;37:100-106 http://dx.doi.org/10.1016/j.bcmd.2006.06.003 PMid:16889993 PMCid:1829476
59. Aboud MR, Ma DD. A comparrision between two activated protein C resistance methods as routine diagnostic tests for factor V Leiden mutation. Br J Haematol. 1997; 97:798-803 http://dx.doi.org/10.1046/j.1365-2141.1997.1432958.x PMid:9217178
60. Gibson CS, MacLennan AH, Rudzki Z, Hague WM, Haan EA, Sharpe P, Priest K, Chan A, Dekker GA; South Australian Cerebral Palsy Research Group. The prevalence of inherited thrombophilias in a Caucasian Australian population. Pathology. 2005;37:160-163 http://dx.doi.org/10.1080/00313020500058250 PMid:16028846
61. Bennett JA, Palmer LJ, Musk AW, Erber WN. Prevalence of factor V Leiden and prothrombin 20210A mutations in indigenous Australians. Thromb Haemost. 2001;86:1592-1593 PMid:11776339
62. Gibson CS, MacLennan AH, Rudzki Z, Hague WM, Haan EA, Sharpe P, Priest K, Chan A, Dekker GA; South Australian Cerebral Palsy Research Group. The prevalence of inherited thrombophilias in a Caucasian Australian population. Pathology. 2005;37:160-163 http://dx.doi.org/10.1080/00313020500058250 PMid:16028846
63. Rosen E, Renbaum P, Heyd J, Levy-Lahad E. High frequency of factor V Leiden in a population of Israeli Arabs. Thromb Haemost. 1999;82:1768 PMid:10613668
64. Arruda VR, Annichino-Bizzacchi JM, Costa FF, Reitsma PH. Factor V Leiden (FVQ 506) is common in a Brazilian population. Am J Hematol. 1995;49:242-243 http://dx.doi.org/10.1002/ajh.2830490312 PMid:7604818
65. Zama T, Murata M, Ono F, Watanabe K, Watanabe R, Moriki T, Yokoyama K, Tokuhira M, Ikeda Y. Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Japanese patients with various forms of thrombosis, and normal individuals. Int J Hematol. 1996;65:71-78 http://dx.doi.org/10.1016/S0925-5710(96)00527-0
66. Fujimura H, Kambayashi J, Monden M, Kato H, Miyata T. Coagulation factor V Leiden mutation may have a racial background. Thromb Haemost. 1995;74:1381-1382 PMid:8607128
67. Kodaira H, Ishida F, Scimodaira S, Takamiya O, Furihata K, Kitano K. Resistance to activated protein C and Arg506Gln factor V mutation are uncommon in eastern Asian populations. Acta Haematol. 1997; 98:22-25 http://dx.doi.org/10.1159/000203548 PMid:9210909
68. Ro A, Hara M, Takada A. The Factor V Leiden and the Prothrombin G20210A mutation was not found in Japanese patients with pulmonary thromboembolism. Thromb Haemost. 1999;82:1769
69. Kim TW, Kim WK, Lee JH, Kim SB, Kim SW, Suh C, Lee KH, Lee JS, Seo EJ, Chi HS, Kim SH. Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep vein thrombosis. J Korean Med Sci. 1998;13:587-590 PMid:9886165 PMCid:3054550
70. Pepe G, Rickards O, Vanegas OC, Brunelli T, Gori AM, Giusti B, Attanasio M, Prisco D, Gensini GF, Abbate R. Prevalence of factor V Leiden mutation in non-European populations. Thromb Haemost. 1997;77:329-331 PMid:9157591
71. Ho CH, Chau WK, Hsu HC, Gau JP, Chih CM. Prevalence of factor V Leiden in the Chinese population. Zhonghua Yi Xue Za Zhi. 1999;62:875-878
72. Lim LC, Tan HH, Lee LH, Tien SL, Abdul Ghafar A. Activated protein C resistance: a study among 60 thromboembolic patients in the Singapore population. Ann Acad Med Singapore. 1999;28:252-255 PMid:10497677
73. Ghosh K, Shetty S, Madkaikar M, Pawar A, Nair S, Khare A, Pathare A, Jijina F, Mohanty D. Venous thromboembolism in young patients from western India: a study. Clin Appl Thromb Hemost. 2001;7:158-165 http://dx.doi.org/10.1177/107602960100700214 PMid:11292195
74. Nasiruddin, Zahur-ur-Rehman, Anwar M, Ahmed S, Ayyub M, Ali W. Frequency of factor V leiden mutation. J Coll Physicians Surg Pak. 2005;15:15-17 PMid:15670517
75. Gregg JP, Yamane AJ, Grody WW. Prevalence of the factor VLeiden mutation in four distinct American ethnic populations. Am J Med Genet. 1997;73:334-336 http://dx.doi.org/10.1002/(SICI)1096-8628(19971219)73:3<334::AID-AJMG20>3.0.CO;2-J
76. Abdulkadir J, Feleke Y, Berg JP, Falch JA and Odegaard OR. Absence of the factor V Leiden mutation in Ethiopians. Thromb Res. 1997;86:431-432 PMid:9211636
77. Vizcaino G, Torres E, Quintero J, Herrmann F, Grimm R, Diez-Ewald M, Arteaga-Vizcaino M, Perez-Requejo JL, Colina-Araujo J. Prevalence of the activated protein C resistance in indigenous and Black populations of the western Venezuela. Invest Clin. 2000;41:29-36 PMid:10758697
78. De Maat MPM, Kluft C, Jespersen J, Gram J. World distribution of factor V Leiden mutation. Lancet. 1996;347:58 http://dx.doi.org/10.1016/S0140-6736(96)91590-1
79. Mathonnet F, Nadifi S, Serazin-Leroy V, Dakouane M, Giudicelli Y. Absence of factor V Leiden mutation and low prothrombin G 20210 A mutation prevalence in a healthy Moroccan population. Thromb Haemost. 2002;88:1073-1074 PMid:12529766
80. They-They TP, Hamzi K, Moutawafik MT, Bellayou H, El Messal M, Nadifi S. Prevalence of angiotensin-converting enzyme, methylenetetrahydrofolate reductase, Factor V Leiden, prothrombin and apolipoprotein E gene polymorphisms in Morocco. Ann Hum Biol. 2010;37:767-777 http://dx.doi.org/10.3109/03014461003738850 PMid:20687780
81. Chafa O, Reghis A, Aubert A, Fischer AM. Prevalence of the FVQ506 (factor V Leiden) mutation in the normal and thrombophilic Algerian population. Br J Haematol. 1997;97:688-689 PMid:9207426
82. Bourouba R, Houcher B, Djabi F, Egin Y, Akar N. The prevalence of methylenetetrahydrofolate reductase 677 C-T, factor V 1691 G-A, and prothrombin 20210 G-A mutations in healthy populations in Setif, Algeria. Clin Appl Thromb Hemost. 2009;15:529-534 http://dx.doi.org/10.1177/1076029608319944 PMid:18840629
83. Frere C, Saut N, Boukef MK, Zili M, Toumi NE. Factor V Leiden G1691A and prothrombin G20210A mutations are common in Tunisia. J Thromb Haemost 2003;1:2451-2452 http://dx.doi.org/10.1046/j.1538-7836.2003.0468b.x PMid:14629484
84. Bouaziz L, Hezard N, Touhami M, Potron G, N'siri B, Nguyen P. Allelic frequency of the factor V Leiden mutation and of the prothrombin gene 20210A mutation in healthy Tunisian population. Thromb Haemost. 2004;91:824-825 PMid:15045148
85. Ajem A, Slama A, Slama FB, Mehjoub T. Prevalence of factor V leiden mutation in patients with thrombosis in Tunisia. East Mediterr Health J. 2009;15:1483-1488 PMid:20218141
86. Maalej L, Hadjkacem B, Ben Amor I, Smaoui M, Gargouri A, Gargouri J. Prevalence of factor V Leiden in south Tunisian blood donors. J Thromb Thrombolysis. 2011 [Epub ahead of print]
87. Zammiti W, Mtiraoui N, Mercier E, Abboud N, Saidi S, Mahjoub T, Almawi WY, Gris JC. Association of factor V gene polymorphisms (Leiden; Cambridge; Hong Kong and HR2 haplotype) with recurrent idiopathic pregnancy loss in Tunisia. A case-control study. Thromb Haemost. 2006;95:612-617. PMid:16601830
88. Mtiraoui N, Borgi L, Hizem S, Nsiri B, Finan RR, Gris JC, Almawi WY, Mahjoub T. Prevalence of antiphospholipid antibodies, factor V G1691A (Leiden) and prothrombin G20210A mutations in early and late recurrent pregnancy loss. Eur J Obstet Gynecol Reprod Biol. 2005;119:164-170. http://dx.doi.org/10.1016/j.ejogrb.2004.07.003
89. Almawi WY, Keleshian SH, Borgi L, Fawaz NA, Abboud N, Mtiraoui N, Mahjoub T. Varied prevalence of factor V G1691A (Leiden) and prothrombin G20210A single nucleotide polymorphisms among Arabs. J Thromb Thrombolysis. 2005;20:163-168 http://dx.doi.org/10.1007/s11239-005-3550-4 PMid:16261289
90. Klai S, Fekih-Mrissa N, Rachdi R, Gritli N. The status of thrombophilic defects and non-O blood group as risk factors for gestational vascular complications among Tunisian women. Acta Haematol. 2011;125:115-120 http://dx.doi.org/10.1159/000321934 PMid:21109732
91. Bouaziz-Borgi L, Nguyen P, Hezard N, Musharrafieh U, Almawi WY, Mahjoub T. A case control study of deep venous thrombosis in relation to factor V G1691A (Leiden) and A4070G (HR2 Haplotype) polymorphisms. Exp Mol Pathol. 2007;83:480-483. http://dx.doi.org/10.1016/j.yexmp.2007.04.006 PMid:17555744
92. Bouaziz-Borgi L, Almawi WY, Mtiraoui N, Nsiri B, Keleshian SH, Kreidy R, Louzir B, Hezard N, Mahjoub T. Distinct association of factor V-Leiden and prothrombin G20210A mutations with deep venous thrombosis in Tunisia and Lebanon. Am J Hematol. 2006;81:641-643. http://dx.doi.org/10.1002/ajh.20582 PMid:16823828
93. El-Karaksy H, El-Koofy N, El-Hawary M, Mostafa A, Aziz M, El-Shabrawi M, Mohsen NA, Kotb M, El-Raziky M, El-Sonoon MA, A-Kader H. Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study. Ann Hematol. 2004;83:712-715 http://dx.doi.org/10.1007/s00277-004-0921-4 PMid:15309526
94. Abu-Skeen IA, Mohamed AA, Moustafa NN, Badawy ME. Factor V Leiden and prothrombin G20210A gene mutations in women with a history of thrombosis during pregnancy. Relation to pregnancy outcomes for mother and fetus. Saudi Med J. 2010;31:123-129 PMid:20174725
95. Maher MM, Soloma SH. Assessment of thrombophilic abnormalities during the active state of inflammatory bowel disease. Saudi J Gastroenterol. 2008;14:192-197 http://dx.doi.org/10.4103/1319-3767.41743 PMid:19568537 PMCid:2702936
96. Settin A, Dowaidar M, El-Baz R, Abd-Al-Samad A, El-Sayed I, Nasr M. Frequency of factor V Leiden mutation in Egyptian cases with myocardial infarction. Hematology. 2008;13:170-174. http://dx.doi.org/10.1179/102453308X316158 PMid:18702875
97. Dashti AA, Jadaon MM, Lewis HL. Factor V Leiden mutation in Arabs in Kuwait by real-time PCR: different values for different Arabs. J Hum Genet. 2010;55:232-235 http://dx.doi.org/10.1038/jhg.2010.11 PMid:20224595
98. Hussein AS, Darwish H, Shelbayeh K. Association between factor V Leiden mutation and poor pregnancy outcomes among Palestinian women. Thromb Res. 2010;126:e78-82. http://dx.doi.org/10.1016/j.thromres.2010.04.017 PMid:20605623
99. Irani-Hakime N, Tamim H, Elias G, Finan RR, Daccache JL, Almawi WY. High prevalence of factor V mutation (Leiden) in the Eastern Mediterranean. Clin Chem. 2000;46:134-136 PMid:10620589
100. Taher A, Khalil I, Shamseddine A, El-Ahdab F, Bazarbachi A. High prevalence of Factor V Leiden mutation among healthy individuals and patients with deep venous thrombosis in Lebanon: is the eastern Mediterranean region the area of origin of this mutation? Thromb Haemost. 2001;86:723-724 PMid:11522037
101. Tamim H, Finan RR, Almawi WY. Prevalence of two thrombophilia predisposing mutations: factor V G1691A (R506Q; Leiden) and prothrombin G20210A, among healthy Lebanese. Thromb Haemost. 2002;88:691-692 PMid:12362248
102. Finan RR, Tamim H, Ameen G, Sharida HE, Rashid M and Almawi WY. Prevalence of factor V G1691A (factor V-Leiden) and prothrombin G20210A gene mutations in a recurrent miscarriage population. Am J Hematol. 2002;71:300-305 http://dx.doi.org/10.1002/ajh.10223 PMid:12447960
103. Isma'eel H, Arnaout MS, Shamseddeen W, Mahfouz R, Zeineh N, Jradi O, Taher A. Screening for inherited thrombophilia might be warranted among Eastern Mediterranean sickle-beta-0 thalassemia patients. J Thromb Thrombolysis. 2006;22:121-123 http://dx.doi.org/10.1007/s11239-006-8953-3 PMid:17008978
104. Zahed LF, Rayes RF, Mahfouz RA, Taher AT, Maarouf HH, Nassar AH. Prevalence of factor V Leiden, prothrombin and methylene tetrahydrofolate reductase mutations in women with adverse pregnancy outcomes in Lebanon. Am J Obstet Gynecol. 2006;195:1114-1118 http://dx.doi.org/10.1016/j.ajog.2006.06.082 PMid:17000243
105. Isma'eel H, El Accaoui R, Shamseddeen W, Taher A, Alam S, Mahfouz R, Arnaout MS. Genetic thrombophilia in patients with VTE in eastern Mediterranean located tertiary care center; is it time to change the algorithm for thrombophilia work up decision making? J Thromb Thrombolysis. 2006;21:267-270 http://dx.doi.org/10.1007/s11239-006-5537-1 PMid:16683219
106. Irani-Hakime N, Tamim H, Elias G, Choueiry S, Kreidy R, Daccache JL, Almawi WY. Factor V R506Q mutation-Leiden: an independent risk factor for venous thrombosis but not coronary artery disease. J Thromb Thrombolysis. 2001;11:111-1116 http://dx.doi.org/10.1023/A:1011268531377 PMid:11406725
107. Irdem A, Devecioglu C, Batun S, Soker M, Sucakli IA. Prevalence of factor V Leiden and prothrombin G20210A gene mutation. Saudi Med J. 2005;26:580-583 PMid:15900364
108. Diz-Kucukkaya R, Hancer VS, Artim-Esen B, Pekcelen Y, Inanc M. The prevalence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome. J Thromb Thrombolysis. 2010;29:303-309 http://dx.doi.org/10.1007/s11239-009-0356-9 PMid:19504051
109. Celiker G, Can U, Verdi H, Yazici AC, Ozbek N, Atac FB. Prevalence of thrombophilic mutations and ACE I/D polymorphism in Turkish ischemic stroke patients. Clin Appl Thromb Hemost. 2009;15:415-420 http://dx.doi.org/10.1177/1076029608315163 PMid:18387982
110. Oguzulgen IK, Yilmaz E, Demirtas S, Erkekol FO, Ekim N, Demir N, Numanoglu N, Ozel D, Ulu A, Akar N. The role of plasminogen activator inhibitor-1 polymorphism, factor-VLeiden, and prothrombin-20210 mutations in pulmonary thromboembolism. Clin Appl Thromb Hemost. 2009;15:73-77 http://dx.doi.org/10.1177/1076029607305110 PMid:18160588
111. Kabukcu S, Keskin N, Keskin A, Atalay E. The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylene tetrahydrofolate reductase C677T gene mutation in healthy population of Denizli, Aegean region of Turkey. Clin Appl Thromb Hemost. 2007;13:166-171 http://dx.doi.org/10.1177/1076029606298990 PMid:17456626
112. Kalkanli S, Ayyildiz O, Tiftik N, Batun S, Isikdogan A, Ince H, Tekes S, Muftuoglu E. Factor V Leiden mutation in venous thrombosis in southeast Turkey. Angiology. 2006;57:193-196 http://dx.doi.org/10.1177/000331970605700209 PMid:16518527
113. Atasay B, Arsan S, Günlemez A, Kemahli S, Akar N.Factor V Leiden and prothrombin gene 20210A variant in neonatal thromboembolism and in healthy neonates and adults: a study in a single center. Pediatr Hematol Oncol. 2003;20:627-634 PMid:14578033
114. Gurgey A, Haznedaroglu IC, Egesel T, Buyukasik Y, Ozcebe OI, Sayinalp N, Dundar SV, Bayraktar Y. Two common genetic thrombotic risk factors: factor V Leiden and prothrombin G20210A in adult Turkish patients with thrombosis. Am J Hematol. 2001;67:107-111 http://dx.doi.org/10.1002/ajh.1087 PMid:11343382
115. Ozbek U, Tangün Y. Frequency of factor V Leiden in Turkey. Int J Hematol. 1996;64:291-292 http://dx.doi.org/10.1016/0925-5710(96)00499-9
116. Angelopoulou K, Nicolaides A, Constantinou Deltas C. Prevalence of genetic mutations that predispose to thrombophilia in a Greek Cypriot population. Clin Appl Thromb Hemost. 2000;6:104-107 http://dx.doi.org/10.1177/107602960000600211 PMid:10775032
117. Eid SS, Rihani G. Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in 200 healthy Jordanians. Clin Lab Sci. 2004; 17:200-202 PMid:15559724
118. Eid SS, Shubeilat T. Prevalence of Factor V Leiden, prothrombin G20210A, and MTHFR G677A among 594 thrombotic Jordanian patients. Blood Coagul Fibrinolysis. 2005;16:417-421 http://dx.doi.org/10.1097/01.mbc.0000175478.46831.52
119. Awidi A, Shannak M, Bseiso A, Kailani MAM, Kailani MA, Omar N, Anshasi B, Sakarneh N. High Prevalence of Factor V Leiden in Healthy Jordanian Arabs. Thromb Haemost. 1999;41:582-584
120. Obeidat NM, Awidi A, Sulaiman NA, Abu-Khader IB. Thrombophilia-related genetic variations in patients with pulmonary embolism in the main teaching hospital in Jordan. Saudi Med J. 2009;30:921-925 PMid:19618008
121. Nusier MK, Radaideh AM, Ababneh NA, Qaqish BM, Alzoubi R, Khader Y, Mersa JY, Irshaid NM, El-Khateeb M. Prevalence of factor V G1691A (Leiden) and prothrombin G20210A polymorphisms among apparently healthy Jordanians. Neuro Endocrinol Lett. 2007;28:699-703 PMid:17984931
122. Al-Sweedan SA, Jaradat S, Iraqi M, Beshtawi M. The prevalence of factor V Leiden (G1691A), prothrombin G20210A and methylenetetrahydrofolate reductase C677T mutations in Jordanian patients with beta-thalassemia major. Blood Coagul Fibrinolysis. 2009;20:675-678 http://dx.doi.org/10.1097/MBC.0b013e3283315b4f
123. Dashti AA, Jadaon MM. Race differences in the prevalence of the factor V Leiden mutation in Kuwaiti nationals. Mol Biol Rep. 2010. http://dx.doi.org/10.1007/s11033-010-0474-7 PMid:21104134
124. Jadaon MM, Dashti AA, Lewis HL. High prevalence of activated protein C resistance and factor V Leiden mutation in an Arab population and patients with venous thrombosis in Kuwait. Diagn Mol Pathol. 2010;19:180-183 http://dx.doi.org/10.1097/00019606-201009000-00009 PMid:20736749
125. Dzimiri N, Meyer B. World distribution of factor V Leiden. Lancet. 1996;347:481-482 http://dx.doi.org/10.1016/S0140-6736(96)90064-1
126. Almawi WY, Tamim H, Kreidy R, Timson G, Rahal E, Nabulsi M, Finan RR, Irani-Hakime N. A case control study on the contribution of factor V-Leiden, prothrombin G20210A, and MTHFR C677T mutations to the genetic susceptibility of deep venous thrombosis. J Thromb Thrombolysis. 2005;19:189-196 http://dx.doi.org/10.1007/s11239-005-1313-x PMid:16082606
127. Pathare A, Al Kindi S, Al Haddabi H, Dennison D, Bayoumi R, Muralitharan S. Hereditary thrombophilia in ethnic Omani patients. Am J Hematol. 2006;81:101-106 http://dx.doi.org/10.1002/ajh.20525 PMid:16432849
128. Pawar AR, Shetty S, Ghosh K, Mohanty D. How old is Factor V Leiden mutation? Thromb Haemost. 2001;86:1591-1592 PMid:11776338
129. Zeinali S, Duca F, Zarbakhsh B, Tagliabue L, Mannucci PM. Thrombophilic mutations in Iran. Thromb Haemost. 2000;83:351-352 PMid:10739401
130. Mozafari H, Rahimi Z, Heidarpour A, Fallahi M, Muniz A. The prevalence of factor V Leiden, prothrombin G20210A and methylenetetrahydrofolate reductase polymorphism C677T among G6PD deficient individuals from Western Iran. Mol Biol Rep. 2009;36:2361-3264 http://dx.doi.org/10.1007/s11033-009-9458-x PMid:19219640
131. Rahimi Z, Nomani H, Mozafari H, Vaisi-Raygani A, Madani H, Malek-Khosravi S, Parsian A. Factor V G1691A, prothrombin G20210A and methylenetetrahydrofolate reductase polymorphism C677T are not associated with coronary artery disease and type 2 diabetes mellitus in western Iran. Blood Coagul Fibrinolysis. 2009;20:252-256 http://dx.doi.org/10.1097/MBC.0b013e3283255487
132. Rahimi Z, Ghaderi M, Nagel RL, Muniz A. Prevalence of thrombotic risk factors among beta-thalassemia patients from Western Iran. J Thromb Thrombolysis. 2008;26:229-233 http://dx.doi.org/10.1007/s11239-007-0163-0 PMid:17982733
133. Rahimi Z, Mozafari H, Shahriari-Ahmadi A, Alimogaddam K, Ghavamzadeh A, Aznab M, Mansouri K, Rezaei M, Parsian A. Deep venous thrombosis and thrombophilic mutations in western Iran: association with factor V Leiden. Blood Coagul Fibrinolysis. 2010;21:385-388 http://dx.doi.org/10.1097/MBC.0b013e328330e69a
134. Lucotte G, Mercier G. Population genetics of factor V Leiden in Europe. Blood Cells Mol Dis. 2001;27:362-367 http://dx.doi.org/10.1006/bcmd.2001.0388 PMid:11259157
135. Cox MJ, Rees DC, Martinson JJ, Clegg JB. Evidence of a single origin of factor V Leiden. Br J Haematol 92(4):1022-1025, 1996. http://dx.doi.org/10.1046/j.1365-2141.1996.4961037.x PMid:8616062
136. Rees DC, Cox M and Clegg JB. World distribution of factor V Leiden. Lancet 346(8983): 1133-1134, 1995. http://dx.doi.org/10.1016/S0140-6736(95)91803-5
137. Perry DJ and Pasi KJ. Resistance to activated protein C and factor V Leiden. Q J Med 90(6): 379-385, 1997
138. Castoldi E, Lunghi B, Mingozzi F, Ioannou P, Marchetti G, Bernardi F. New coagulation factor V gene polymorphisms define a single and infrequent haplotype underlying the factor V Leiden mutation in Mediterranean populations and Indians. Thromb Haemost. 1997;78:1037-1041 PMid:9308750
139. Bauduer F, Lacombe D. Factor V Leiden, prothrombin 20210A, methylenetetrahydrofolate reductase 677T, and population genetics. Mol Genet Metab 2005;86:91-99 http://dx.doi.org/10.1016/j.ymgme.2005.04.002 PMid:16185908
140. Jadaon MM, Dashti AA, Lewis HL. What is the origin of factor V Leiden mutation in Arabs? The first molecular proof. J Thromb Haemost. 2011;9: P-MO-155.